187 related articles for article (PubMed ID: 36083121)
1. Clinical response to belumosudil in bronchiolitis obliterans syndrome: a combined analysis from 2 prospective trials.
DeFilipp Z; Kim HT; Yang Z; Noonan J; Blazar BR; Lee SJ; Pavletic SZ; Cutler C
Blood Adv; 2022 Dec; 6(24):6263-6270. PubMed ID: 36083121
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of belumosudil for chronic graft-versus-host disease in patients who failed at least one line of systemic therapy in China.
Wang Y; Wu D; Zhang X; Li Y; He Y; Liu Q; Xuan L; Li Z; Qi K; Sun Y; Wang S; Mo W; Gao L; Hua Y; Wang Y; Zhang Y
BMC Med; 2024 Mar; 22(1):142. PubMed ID: 38532458
[TBL] [Abstract][Full Text] [Related]
3. Inert Gas Washout in Bronchiolitis Obliterans Following Hematopoietic Cell Transplantation.
Nyilas S; Baumeler L; Tamm M; Halter JP; Savic S; Korten I; Meyer A; Singer F; Passweg JR; Latzin P; Stolz D
Chest; 2018 Jul; 154(1):157-168. PubMed ID: 29275133
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of safety and efficacy of allogeneic adipose tissue-derived mesenchymal stem cells in pediatric bronchiolitis obliterans syndrome (BoS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
Mohseni R; Mahdavi Sharif P; Behfar M; Modaresi MR; Shirzadi R; Mardani M; Jafari L; Jafari F; Nikfetrat Z; Hamidieh AA
Stem Cell Res Ther; 2023 Sep; 14(1):256. PubMed ID: 37726865
[TBL] [Abstract][Full Text] [Related]
5. A critical review of belumosudil in adult and pediatric patients with chronic graft-versus-host disease.
Salhotra A; Sandhu K; O'Hearn J; Ali H; Nakamura R; Modi BG
Expert Rev Clin Immunol; 2023 Mar; 19(3):241-251. PubMed ID: 36440483
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Value of Cutaneous Disease Severity Estimates on Survival Outcomes in Patients With Chronic Graft-vs-Host Disease.
Baumrin E; Baker LX; Byrne M; Martin PJ; Flowers ME; Onstad L; El Jurdi N; Chen H; Beeghly-Fadiel A; Lee SJ; Tkaczyk ER
JAMA Dermatol; 2023 Apr; 159(4):393-402. PubMed ID: 36884224
[TBL] [Abstract][Full Text] [Related]
7. A review of the therapeutic potential of the cysteinyl leukotriene antagonist Montelukast in the treatment of bronchiolitis obliterans syndrome following lung and hematopoietic-stem cell transplantation and its possible mechanisms.
Kordjazy N; Amini S
Ther Adv Respir Dis; 2024; 18():17534666241232284. PubMed ID: 38504551
[TBL] [Abstract][Full Text] [Related]
8. Risk Factors for Bronchiolitis Obliterans Syndrome after Initial Detection of Pulmonary Impairment after Hematopoietic Cell Transplantation.
Alkhunaizi M; Patel B; Bueno L; Bhan N; Ahmed T; Arain MH; Saliba R; Rondon G; Dickey BF; Bashoura L; Ost DE; Li L; Wang S; Shpall E; Champlin RE; Mehta R; Popat UR; Hosing C; Alousi AM; Sheshadri A
Transplant Cell Ther; 2023 Mar; 29(3):204.e1-204.e7. PubMed ID: 36503180
[TBL] [Abstract][Full Text] [Related]
9. ROCK2 Inhibition With Belumosudil (KD025) for the Treatment of Chronic Graft-Versus-Host Disease.
Jagasia M; Lazaryan A; Bachier CR; Salhotra A; Weisdorf DJ; Zoghi B; Essell J; Green L; Schueller O; Patel J; Zanin-Zhorov A; Weiss JM; Yang Z; Eiznhamer D; Aggarwal SK; Blazar BR; Lee SJ
J Clin Oncol; 2021 Jun; 39(17):1888-1898. PubMed ID: 33877856
[TBL] [Abstract][Full Text] [Related]
10. Epidemiology of Lower Respiratory Tract Infections and Community-Acquired Respiratory Viruses in Patients with Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation: A Retrospective Cohort Study.
Epstein DJ; Liang EC; Sharifi H; Lai YK; Arai S; Graber-Naidich A; Sundaram V; Nelson J; Hsu JL
Transplant Cell Ther; 2022 Oct; 28(10):705.e1-705.e10. PubMed ID: 35872303
[TBL] [Abstract][Full Text] [Related]
11. Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study.
Cutler C; Lee SJ; Arai S; Rotta M; Zoghi B; Lazaryan A; Ramakrishnan A; DeFilipp Z; Salhotra A; Chai-Ho W; Mehta R; Wang T; Arora M; Pusic I; Saad A; Shah NN; Abhyankar S; Bachier C; Galvin J; Im A; Langston A; Liesveld J; Juckett M; Logan A; Schachter L; Alavi A; Howard D; Waksal HW; Ryan J; Eiznhamer D; Aggarwal SK; Ieyoub J; Schueller O; Green L; Yang Z; Krenz H; Jagasia M; Blazar BR; Pavletic S
Blood; 2021 Dec; 138(22):2278-2289. PubMed ID: 34265047
[TBL] [Abstract][Full Text] [Related]
12. Prospective Phase II Trial of Montelukast to Treat Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation and Investigation into Bronchiolitis Obliterans Syndrome Pathogenesis.
Williams KM; Pavletic SZ; Lee SJ; Martin PJ; Farthing DE; Hakim FT; Rose J; Manning-Geist BL; Gea-Banacloche JC; Comis LE; Cowen EW; Justus DG; Baird K; Cheng GS; Avila D; Steinberg SM; Mitchell SA; Gress RE
Transplant Cell Ther; 2022 May; 28(5):264.e1-264.e9. PubMed ID: 35114411
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with bronchiolitis obliterans syndrome and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Gazourian L; Rogers AJ; Ibanga R; Weinhouse GL; Pinto-Plata V; Ritz J; Soiffer RJ; Antin JH; Washko GR; Baron RM; Ho VT
Am J Hematol; 2014 Apr; 89(4):404-9. PubMed ID: 24375545
[TBL] [Abstract][Full Text] [Related]
14. CD19(+)CD21(low) B cells and patients at risk for NIH-defined chronic graft-versus-host disease with bronchiolitis obliterans syndrome.
Kuzmina Z; Krenn K; Petkov V; Körmöczi U; Weigl R; Rottal A; Kalhs P; Mitterbauer M; Ponhold L; Dekan G; Greinix HT; Pickl WF
Blood; 2013 Mar; 121(10):1886-95. PubMed ID: 23303823
[TBL] [Abstract][Full Text] [Related]
15. A Multiparameter Prognostic Risk Score of Chronic Graft-versus-Host Disease Based on CXCL10 and Plasmacytoid Dendritic Cell Levels in the Peripheral Blood at 3 Months after Allogeneic Hematopoietic Stem Cell Transplantation.
Chirumbolo G; Dicataldo M; Barone M; Storci G; De Matteis S; Laprovitera N; Sinigaglia B; Barbato F; Maffini E; Cavo M; Bonifazi F; Arpinati M
Transplant Cell Ther; 2023 May; 29(5):302.e1-302.e8. PubMed ID: 36796518
[TBL] [Abstract][Full Text] [Related]
16. Correlation of Patient-Reported Outcomes with Clinical Organ Responses: Data from the Belumosudil Chronic Graft-versus-Host Disease Studies.
Lee SJ; Cutler C; Blazar BR; Tu A; Yang Z; Pavletic SZ
Transplant Cell Ther; 2022 Oct; 28(10):700.e1-700.e6. PubMed ID: 35781099
[TBL] [Abstract][Full Text] [Related]
17. A personalized, organ-based approach to the treatment of chronic steroid-refractory graft-versus-host disease.
Fatoum H; Zeiser R; Hashmi SK
Blood Rev; 2024 Jan; 63():101142. PubMed ID: 38087715
[TBL] [Abstract][Full Text] [Related]
18. Bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation-an increasingly recognized manifestation of chronic graft-versus-host disease.
Chien JW; Duncan S; Williams KM; Pavletic SZ
Biol Blood Marrow Transplant; 2010 Jan; 16(1 Suppl):S106-14. PubMed ID: 19896545
[TBL] [Abstract][Full Text] [Related]
19. Frailty in Patients with Chronic Graft-versus-Host Disease.
Rashid N; Arora M; Jurdi NE; Onstad L; Pidala JA; Flowers ME; Lee SJ
Transplant Cell Ther; 2023 Jun; 29(6):367-374. PubMed ID: 36921916
[TBL] [Abstract][Full Text] [Related]
20. Effect of Ruxolitinib on Lung Function after Allogeneic Stem Cell Transplantation.
Bondeelle L; Chevret S; Hurabielle C; Samy L; Goletto T; Costantini A; Sicre de Fontbrune F; Michonneau D; Socié G; Tazi A; Bouaziz JD; Bergeron A
Biol Blood Marrow Transplant; 2020 Nov; 26(11):2115-2120. PubMed ID: 32738501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
